What’s Trending in Oncology? A Discussion Following ASCO 2026 with Anne Marie Robertson From EVERSANA

Key Takeaways

• Bispecific antibodies and small molecules showed dramatic outcome improvements
• AI platform Gemini will be available to all ASCO members
• Patient identification variability hampers targeted therapy rollout globally
• Post‑infusion care for bispecifics demands new infrastructure
• Agile partnership models are essential to navigate oncology commercialization uncertainty

Pulse Analysis

ASCO 2026 underscored how precision medicine is moving from concept to clinic at unprecedented speed. Breakthroughs such as daraxonrasib, which targets a mutation present in over 90% of pancreatic cancers, and the latest CROWN data for ALK‑positive non‑small cell lung cancer demonstrated tangible survival gains. These advances, driven by bispecific antibodies and next‑generation small molecules, are reshaping treatment algorithms and creating new revenue opportunities for biopharma, while also raising expectations for rapid market entry.

A parallel storyline was the formal introduction of Google’s Gemini AI platform to all ASCO members. This move marks a transition from pilot projects to everyday clinical practice, where AI now assists physicians with diagnostic imaging, streamlines trial data analysis, and reduces administrative burdens. For commercial teams, AI‑enabled insights accelerate patient‑segmentation, forecast demand, and refine value‑based pricing models, turning data into a competitive differentiator rather than a novelty.

The scientific momentum brings operational challenges that cannot be ignored. Variability in global screening practices limits patient identification for highly targeted therapies, and the complex logistics of post‑infusion care for bispecifics demand new infrastructure and support services. Robertson highlighted that flexible, partnership‑centric models—exemplified by EVERSANA—allow emerging biotech firms to adapt quickly to shifting trial outcomes and access hurdles. Leaders must invest in dynamic pipeline monitoring and align commercial, access, and patient‑service functions early, compressing the window between data readout and market launch to stay ahead in an increasingly agile oncology landscape.